

Maria Ricci Memorial Lectureship in Oncology 2022

Advances in Systemic Therapy for Prostate Cancer: From Palliative to Precision



KIM CHI, MD, FRCPC

Kim Chi is a medical oncologist and the Chief Medical Officer of BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia in Canada. He is also Professor of Medicine at the University of British Columbia in Vancouver.

Prof. Chi's research in the field of genitourinary cancers focuses on prostate cancer and investigational new drugs, where he has contributed to changing international standards of care practice for patients with advanced prostate cancer. Recently, he has been investigating circulating tumour DNA as a potential prognostic and predictive biomarker for patients with castration-resistant prostate cancer.

Prof. Chi is the past-Chair of the CCTG Genitourinary Disease Site Committee and has held peer-reviewed grant funding from the Canada Institutes of Health Research, National Cancer Institute of Canada/Canadian Cancer Society, the US Department of Defence, Movember, Prostate Cancer Foundation (USA), and Prostate Cancer Canada.

Prof. Chi has published widely in prestigious peer-reviewed journals, including most recently the *Journal of Clinical Oncology*, *Annals of Oncology*, the *New England Journal of Medicine*, and *Lancet Oncology*.

Saturday, 30 April 2022

3:30 pm

This lectureship was established in September 2007 by a donation from GlaxoSmithKline Inc. in memory of Maria Ricci.



Maria Ricci

June 15, 1974 – January 24, 2007

Maria Ricci was GlaxoSmithKline's Scientific Development Manager in oncology when her life ended tragically while traveling on GSK-related business. She was a PhD candidate in Microbiology & Immunology at McGill University and received her MSc in pharmacology and toxicology from the University of Western Ontario.

Maria was well respected by her colleagues and peers for her commitment to making a difference for Canadian patients and is remembered for her enthusiasm and passionate approach to work and life.

Maria was instrumental in bridging relationships between global GSK and the Canadian medical community and facilitated Canadian scientific and medical engagement in the development of GSK's oncology pipeline.